Latest News and Press Releases

Marseille, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020...

The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy MARSEILLE, France, April 21, 2021 (GLOBE...

L’Assemblée Générale sera retransmise en direct par la Société Les actionnaires sont invités à voter à l’Assemblée Générale par correspondance ou par procuration Marseille, France, 21 avr. 2021 ...

The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy Marseille, France, April 21, 2021 (GLOBE...

Marseille, France, 19 avr. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate...

Marseille, France, April 19, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...

MARSEILLE, France, April 19, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...

Marseille, 18 mars 2021 (GLOBE NEWSWIRE) -- Lacutamab a reçu le statut « PRIME » de l’Agence Européenne du Médicament dans le syndrome de Sézary ; le programme de développement clinique avance dans...

Marseille, March 18, 2021 (GLOBE NEWSWIRE) -- Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides...

Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphomaCompany’s first NK...